We have just released the latest update to the Open Targets Platform — 23.06.
Key highlights for this release:
This release integrates 15,117,741 evidence strings to build 7,835,247 target-disease associations between 24,713 diseases and 62,685 targets from the following 23 public resources:
- 2,742,321 genetic evidence from European Variation Archive (EVA)
- 782,147 genetic evidence from Open Targets Genetics
- 2,990 genetic evidence from Gene2Phenotype
- 31,002 genetic evidence from the Genomics England PanelApp
- 2,071 genetic evidence from ClinGen
- 6,246 genetic evidence from Orphanet
- 27,373 genetic evidence from Gene burden
- 24,304 genetic evidence from CRISPRBrain
- 4,164 genetic evidence from UniProt Literature
- 17,007 somatic evidence from European Variation Archive (EVA)
- 4,350 somatic evidence from intOGen
- 76,292 somatic evidence from the Cancer Gene Census
- 26,384 somatic evidence from Uniprot
- 612,358 drug evidence from ChEMBL
- 230,902 expression evidence from Expression Atlas
- 10,276 affected pathway evidence from Reactome
- 72,294 affected pathway evidence from SLAPenrich
- 378 affected pathway evidence from PROGENy
- 389 systems biology evidence from SysBio
- 1,298 somatic evidence from the Cancer Genome Interpreter
- 1,838 CRISPR-Cas9 (Cancer Cell Lines) evidence from Behan et al. 2019
- 1,021,202 mouse model evidence from IMPC
- 9,420,155 scientific literature evidence from co-occurence mining in Europe PMC
Additionally, the Platform now allows users to explore data on 13,210 drugs.
For more details, read the 23.06 blog post.